10 Million People Started Trading Last Year – Here’s What to Do Next
How do you make money trading?
What are the secrets pros use to beat the market day after day?
Former Chicago Board Options Exchange trader reveals all the insider tricks...
Get the Full Report Now (No Credit Card Required... Limited Time Only)
Juan Andres, insider at Moderna

Juan Andres Insider Information

Insider of Moderna
Juan Andres serves as Chief Technical Operations and Quality Officer of the Company. He joined the Company in August 2017, and has served as our Chief Technical Operations and Quality Officer since August 2018. Before joining the Company, Mr. Andres worked at Novartis AG (NYSE: NVS) from 2005 to 2017, in various roles of increasing responsibility including serving as Global Head, Technical Operations (Manufacturing and Supply Chain), Global Head of Quality, and Global Head of Technical Research and Development. From 1987 to 1996, Mr. Andres served in various manufacturing, production, and quality roles at Eli Lilly and Company (NYSE: LLY), including as Vice President, Pharmaceutical Manufacturing. Mr. Andes has served as a member of the board of directors of Evelo Biosciences, Inc. (Nasdaq: EVLO) since December 2019, and of Avantor, Inc. (NYSE: AVTR), since September 2019. Mr. Andres obtained a degree in pharmacy at the Universidad de Alcalá in Spain.

What is Juan Andres' net worth?

The estimated net worth of Juan Andres is at least $1.77 million as of July 23rd, 2021. Mr. Andres owns 5,000 shares of Moderna stock worth more than $1,768,000 as of July 31st. This net worth evaluation does not reflect any other assets that Mr. Andres may own. Additionally, Mr. Andres receives an annual salary of $1,250,000.00 as Insider at Moderna.

How old is Juan Andres?

Mr. Andres is currently 56 years old. There are 6 older executives and no younger executives at Moderna. The oldest executive at Moderna is Mr. David W. Meline, CFO & Principal Accounting Officer, who is 64 years old.

What is Juan Andres' salary?

As the Insider of Moderna, Inc., Mr. Andres earned a total compensation package of $4,247,823.00 in 2020. Mr. Andres earned a salary of $548,712.00, a bonus of $662,400.00, stock awards of $750,000.00, options awards of $2,250,000.00, and other compensation of $36,711.00.There are 2 executives that earn more than Mr. Andres. The highest earning executive at Moderna is Mr. Stephane Bancel, CEO & Director, who commands a salary of $3,860,000.00 per year.

How do I contact Juan Andres?

The corporate mailing address for Mr. Andres and other Moderna executives is 200 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. Moderna can also be reached via phone at 617-714-6500 and via email at [email protected]

Has Juan Andres been buying or selling shares of Moderna?

During the past quarter, Juan Andres has sold $13,950,400.00 in Moderna stock. Most recently, Juan Andres sold 5,000 shares of the business's stock in a transaction on Wednesday, July 28th. The shares were sold at an average price of $332.92, for a transaction totalling $1,664,600.00.

Who are Moderna's active insiders?

Moderna's insider roster includes Noubar Afeyan (Director), Noubar Afeyan (Director), Juan Andres (Insider), Stephane Bancel (CEO), Lori Henderson (General Counsel), Stephen Hoge (President), and Tal Zaks (Insider).

Are insiders buying or selling shares of Moderna?

During the last year, Moderna insiders bought shares 3 times. They purchased a total of 423,616 shares worth mmore than $15,619,184.48. During the last year, insiders at the sold shares 197 times. They sold a total of 7,319,287 shares worth mmore than $1,033,415,369.93. The most recent insider tranaction occured on July, 28th when Stephane Bancel CEO bought 9,000 shares worth more than $2,996,280.00. Insiders at Moderna own 19.4 % of the company.

Information on this page was last updated on 7/28/2021.

Juan Andres Insider Trading History at Moderna

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/28/2021Sell5,000$332.92$1,664,600.00View SEC Filing Icon  
7/23/2021Sell5,000$330.90$1,654,500.005,000View SEC Filing Icon  
7/21/2021Sell5,000$299.00$1,495,000.005,000View SEC Filing Icon  
7/19/2021Sell15,000$284.40$4,266,000.00View SEC Filing Icon  
7/16/2021Sell5,000$276.51$1,382,550.00View SEC Filing Icon  
7/14/2021Sell5,000$237.22$1,186,100.00View SEC Filing Icon  
7/12/2021Sell5,000$230.71$1,153,550.00View SEC Filing Icon  
7/6/2021Sell5,000$229.62$1,148,100.00View SEC Filing Icon  
6/23/2021Sell5,000$219.65$1,098,250.005,000View SEC Filing Icon  
6/21/2021Sell5,000$200.86$1,004,300.005,000View SEC Filing Icon  
6/14/2021Sell5,000$213.32$1,066,600.005,000View SEC Filing Icon  
6/7/2021Sell5,000$207.04$1,035,200.005,000View SEC Filing Icon  
5/5/2021Sell5,000$178.34$891,700.005,000View SEC Filing Icon  
4/28/2021Sell5,000$182.32$911,600.005,000View SEC Filing Icon  
4/26/2021Sell5,000$171.77$858,850.005,000View SEC Filing Icon  
4/21/2021Sell5,000$158.60$793,000.005,000View SEC Filing Icon  
4/19/2021Sell5,000$166.17$830,850.005,000View SEC Filing Icon  
4/14/2021Sell5,000$153.75$768,750.005,000View SEC Filing Icon  
4/7/2021Sell5,000$131.63$658,150.005,000View SEC Filing Icon  
3/29/2021Sell5,000$130.05$650,250.005,000View SEC Filing Icon  
3/17/2021Sell5,000$149.78$748,900.005,000View SEC Filing Icon  
3/10/2021Sell5,000$133.24$666,200.005,000View SEC Filing Icon  
2/1/2021Sell5,000$172.99$864,950.005,000View SEC Filing Icon  
1/11/2021Sell5,000$112.83$564,150.005,000View SEC Filing Icon  
5/13/2020Sell127,500$64.67$8,245,425.00127,500View SEC Filing Icon  
5/1/2020Sell25,000$48.05$1,201,250.0025,000View SEC Filing Icon  
4/15/2020Sell23,403$37.11$868,485.3323,403View SEC Filing Icon  
4/6/2020Sell300$35.13$10,539.00300View SEC Filing Icon  
See Full Table

Juan Andres Buying and Selling Activity at Moderna

This chart shows Juan Andres's buying and selling at Moderna by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Moderna Company Overview

Moderna logo
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $353.60
Low: $342.28
High: $359.90

50 Day Range

MA: $238.47
Low: $164.17
High: $353.60

2 Week Range

Now: $353.60
Low: $54.21
High: $362.00


11,345,689 shs

Average Volume

19,917,172 shs

Market Capitalization

$141.98 billion

P/E Ratio


Dividend Yield



10 Million People Started Trading Last Year – Here’s What to Do Next
How do you make money trading?
What are the secrets pros use to beat the market day after day?
Former Chicago Board Options Exchange trader reveals all the insider tricks...
Get the Full Report Now (No Credit Card Required... Limited Time Only)